Health
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine – GlobeNewswire
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection …
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection
Supports the Development of New Approaches to Treat Multiple Neurological Diseases
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) — CytoDel, Inc. (CytoDel or the Company), a privately-held corporation, today announces the publication of preclinical data on the Companys lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine….
-
Noosa News9 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General15 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965
-
Noosa News17 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family
-
Noosa News11 hours agoWomen’s Softball World Cup 2027 Redcliffe Brisbane